Overview:
The broadening range of therapies for patients with newly diagnosed multiple myeloma (NDMM) has led to improved patient outcomes, but there remains a need for induction regimens that reduce the risk of relapse. Increasingly, the treatment of patients with NDMM is incorporating anti-CD38 antibodies and second-generation proteasome inhibitors into quadruplet regimens for transplant-eligible and transplant-ineligible patients. Newer regimens are providing much-needed options for patients, but also introduce new challenges for busy clinicians navigating an increasingly complex treatment landscape.
This virtual CME-certified symposium will feature MM experts who will review the latest clinical trial data and address issues that clinicians face on a daily basis, including choosing between triplet and quadruplet therapies, evaluating patients for transplant, and assessing the role for minimal residual disease testing. Additionally, future approaches under investigation for patients with NDMM will be previewed, including regimens with cellular therapies and bispecific antibodies.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Analyze efficacy and safety data from recent clinical trials evaluating quadruplet therapy in patients with newly diagnosed multiple myeloma (NDMM)
- Assess evolving evidence on the use of minimal residual disease assessments to guiding choice and duration of maintenance therapy
- Balance disease- and patient-specific factors to formulate individualized treatment plans for patients with NDMM
- Implement proactive measures to mitigate treatment-related adverse events in patients with NDMM
C. Ola Landgren, MD, PhD
Professor of Medicine, University of Miami
Chief, Division of Myeloma & Myeloma Institute
Paul J. DiMare Endowed Chair in Immunotherapy
Chief, Riney Family Multiple Myeloma Research Program
Co-Director, Translational and Clinical Oncology Program
Sylvester Comprehensive Cancer Center
Professor of Medicine
University of Miami Leonard M. Miller School of Medicine
Miami, Florida
Mohamad Mohty, MD, PhD
Professor of Hematology
Head of the Hematology and Cellular Therapy Department Saint-Antoine Hospital
Sorbonne University
Paris, France
Surbhi Sidana, M.D.
Associate Professor of Medicine
Director, Myeloma Disease Focused Group
Division of BMT & Cell Therapy
Stanford University
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
Physicians' Education Resource is proud to partner with The International Academy for Clinical Hematology (IACH)
